Treatment of Gorham-Stout disease with zoledronic acid and interferon-α: a case report and literature review.
Gorham-Stout disease is a rare disease characterized by osteolysis, angiomatosis, and soft-tissue swelling. It is a diagnosis of exclusion and has an unknown etiology. Chylothorax is a common complication of the disease that is associated with a high mortality rate. There is no standard of treatment. We report a case of a 16-year-old female with Gorham-Stout disease and recurrent pleural effusions who was successfully treated with concurrent zoledronic acid and peg-interferon α-2b.
Kuriyama
Dawn K
DK
Family Medicine Residency, University of Hawaii, Honolulu, HI, USA.
McElligott
Sean C
SC
Glaser
Darryl W
DW
Thompson
Karen S
KS
D000293:Adolescent; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D047630:Depsipeptides; D004164:Diphosphonates / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005670:Fusarium; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D010015:Osteolysis, Essential / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D010996:Pleural Effusion / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D047630:Depsipeptides; D004164:Diphosphonates; D007093:Imidazoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C014001:fusafungin; D000077211:Zoledronic Acid; C417083:peginterferon alfa-2b